Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Papillomavirus Infections 9Uterine Cervical Neoplasms 4Neuroendocrine Tumors 4Autoimmune Diseases 3Prostatic Neoplasms 2Neoplasms 2Abortion, Spontaneous 2Recurrence 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neuroblastoma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × Data Collection × Clear all
NCT04253015 2024-02-07

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

RECORDATI GROUP

Recruiting
125 enrolled
CNS

Brain Neoplasms, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡